Abstract
Introduction Psychiatric disorders are diagnosed according to diagnostic criteria such as the DSM-5 and ICD-11. Basically, psychiatrists extract symptoms and make a diagnosis by conversing with patients. However, such processes often lack objectivity. In contrast, specific linguistic features can be observed in some psychiatric disorders, such as a loosening of associations in schizophrenia. The purposes of the present study are to quantify the language features of psychiatric disorders and neurocognitive disorders using natural language processing and to identify features that differentiate disorders from one another and from healthy subjects.
Methods This study will have a multi-center prospective design. Major depressive disorder, bipolar disorder, schizophrenia, anxiety disorder including obsessive compulsive disorder and, major and minor neurocognitive disorders, as well as healthy subjects will be recruited. A psychiatrist or psychologist will conduct 30-to-60-min interviews with each participant and these interviews will be recorded using a microphone headset. In addition, the severity of disorders will be assessed using clinical rating scales. Data will be collected from each participant at least twice during the study period and up to a maximum of five times.
Discussion The overall goal of this proposed study, the Understanding Psychiatric Illness Through Natural Language Processing (UNDERPIN), is to develop objective and easy-to-use biomarkers for diagnosing and assessing the severity of each psychiatric disorder using natural language processing. As of August 2021, we have collected a total of >900 datasets from >350 participants. To the best of our knowledge, this data sample is one of the largest in this field.
Trial registration UMIN000032141, University Hospital Medical Information Network (UMIN).
Competing Interest Statement
T. Kishimoto has received consultant fees from FRONTEO. Yoko Eguchi has received speaker's honoraria from Eisai. TH received speaker's honoraria from Yoishi-tomi. T. Kikuchi has received speaker's honoraria from Astellas, Dai-nippon Sumitomo, Eli Lilly, Janssen, MSD, Otsuka, Yoshitomi Yakuhin, Pfizer, and Takeda. JM has received speaker's honoraria from Eli Lilly, Janssen, Otsuka, MSD, Shionogi, and Pfizer. MM has received speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin. Also he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura. Other authors have no conflict of interest.
Funding Statement
This research is supported by the Japan Science and Technology Agency CREST under Grant Number JPMJCR1684 and JPMJCR19F4. A former grant was awarded in 2016 and ended in 2018. A latter grant was awarded in 2019 and will end in 2021. The funding source did not participate in the design of this study and will not be involved in the study's execution, analyses, or submission of results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Keio University School of Medicine and the participating medical facilities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not available due to ethical restrictions
Abbreviations
- UNDERPIN
- Understanding Psychiatric Illness Through Natural Language Processing
- DSM-5
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
- ICD-11
- International Classification of Diseases 11th Revision
- UMIN
- University Hospital Medical Information Network
- M.I.N.I.
- Mini-International Neuropsychiatric Interview
- MMSE
- Mini-Mental State Examination Mini-International; Neuropsychiatric Interview
- QOL
- Quality Of Life
- YLDs
- years lived with disability
- CGI-S
- Clinical General Impression Scale-Severity
- SCID
- Structural Clinical Interview for DSM-5
- HAM-D
- Hamilton Depression Rating Scale
- MADRS
- Montgomery Asberg Depression Rating Scale
- YMRS
- Young Mania Rating Scale
- STAI
- State-Trait Anxiety Inventory
- PANSS
- Positive And Negative Syndrome Scale
- MMSE
- Mini-Mental State Examination
- MoCA-J
- Montreal Cognitive Assessment-Japanese version
- WMS-RLM
- Wechsler Memory Scale-Revised Logical Memory
- CDR
- Clinical Dementia Rating
- F0
- fundamental Frequency
- F1
- 1st formant Frequency
- F2
- 2nd formant Frequency
- F3
- 3rd formant Frequency
- CPP
- Cepstral Peak Prominence
- MFCC
- Mel-Frequency Cepstrum Coefficients
- SVM
- support vector machines
- DUP
- duration of untreated psychosis
